Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India Upholds Prevnar 13 Patent In Big Win For Pfizer

Executive Summary

India has awarded Pfizer a patent for its blockbuster pneumonia vaccine Prevnar13, handing the pharmaceutical giant a big victory in a case which has been closely watched as a key test of the country’s patentability criteria.

You may also be interested in...



Serum Institute Awaiting Gavi Push For $2 Pneumococcal Vaccine

Serum Institute hopes to hear by May from Gavi on whether it will consider the firm's $2 per dose pneumococcal conjugate vaccine for immunization programs across developing countries. Its 10-valent vaccine, versus GSK’s 11-valent and Pfizer’s 13-valent vaccines, is 30% cheaper.

India Flouting Own Patent Law By Giving IP Protection To Undeserving Drugs?

India is known for its strict patent legislation restricting which drugs can be given IP protection, but a new study suggests authorities in the country are actually being too lenient in awarding patents in a rush to grant new applications.

US IP Index Based On 'Flawed' Assumptions, Claim Indian Pharma Firms

Indian drug makers have blasted the US Chamber of Commerce’s Global Innovation Policy Center over its International IP Index, saying its compilation is based on a “flawed” assumption that stronger patents drive greater innovation, and that it ignores individual national concerns.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC099362

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel